Search Results

You are looking at 11 - 20 of 738 items for :

  • "risk factors" x
  • Refine by Access: All x
Clear All
Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao

of a given patient's FN risk depends on knowledge of key FN risk factors. The performance of currently available FN prediction models in the literature indicated room for improvement in clinical FN risk prediction. 18 , 19 Thus, the objective of this

Full access

Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow

) view/print certificate. Release date: May 12, 2016; Expiration date: May 12, 2017 Learning Objectives Upon completion of this activity, participants will be able to: Identify risk factors associated with refusal of recommended chemotherapy

Full access

Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen

summarized and compared between those with and without SREs using the Fisher exact test for the categorical risk factors and the Kruskal-Wallis test for the continuous variables. All statistical analyses were performed using SAS, version 9.4 (SAS Institute

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

critical issue for all cancer patients, regardless of other risk factors, and should be incorporated into comprehensive cancer care. An American Society of Clinical Oncology (ASCO) Task Force statement on bone health in women with breast cancer noted, “Many

Full access

Sofia D. Merajver and Kara Milliron

National Cancer Data Base, 2000 . CA Cancer J Clin 2000 ; 50 : 171 – 183 . 3 Dupont WD Page DL . Risk factors for breast cancer in women with proliferative breast disease . N Engl J Med 1985 ; 312 : 146 – 151 . 4 Slattery ML

Full access

Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative

LR (whether unifocal or multicentric), independent risk factors for LR, and 2-year DFS and OS rates. DFS was defined as patients who were alive without evidence of local or distant recurrence. OS was defined as those who were alive with or without

Full access

Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative

of LR (whether unifocal or multicentric), independent risk factors for LR, and 2-year DFS and OS rates. DFS was defined as patients who were alive without evidence of local or distant recurrence. OS was defined as those who were alive with or

Full access

John Fanikos and Samuel Z. Goldhaber

: a 25 year population based study . Arch Intern Med 1998 ; 15 : 585 – 593 . 5. Heit JA Silverstein MD Mohr DN . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study . Arch Intern Med

Full access

Mohammad Abu Zaid, Paul C. Dinh Jr, Patrick O. Monahan, Chunkit Fung, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra Althouse, Shirin Ardeshir-Rouhani-Fard, Howard D. Sesso, Robert Huddart, Taisei Mushiroda, Michiaki Kubo, M. Eileen Dolan, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group

Platinum Study ( P =.30), and other clinical and sociodemographic characteristics ( supplemental eTable 1 , available with this article at JNCCN.org ). Data on the prevalence of metabolic syndrome and its risk factors in this cohort have been previously

Full access

Amol K. Narang and Stephanie A. Terezakis

considered a standard regimen, with a higher number of chemotherapy cycles and/or radiation dose depending on number of risk factors, initial bulk, and response to treatment. Table 1 Definitions of Unfavorable Risk Factors by Specific Cooperative